单克隆抗体（mAbs）的治疗应用范围广泛，从癌症治疗到免疫介导的疾病，涵盖感染和心血管疾病等。改进的治疗性抗体发现方法的发展加速了大量mAbs的识别：一个发现项目可以深入挖掘，并针对感兴趣的靶标产生数百甚至数千个潜在的抗体线索。需要高通量的mAb表达和纯化方法来快速验证这些线索。在本研究中，我们描述了一种以蛋白A涂层膜板系统，Purexa™ AHT膜板，用于对数百个重组mAbs进行可靠的制备纯化，无需自动化。高效率（>80%）的恢复产生了足够的mAb用于下游筛选分析，如ELISA和表面等离子共振（SPR）。这个新系统使得无论操作规模如何，都可以及时地对发现项目中的数百个主导抗体进行功能验证。版权所有 © 2023 Elsevier B.V. 发布。

The therapeutic use of monoclonal antibodies (mAbs) ranges from cancer treatment to immune-mediated conditions, covering infectious and cardiovascular disorders, among others. The development of improved methods for therapeutic antibody discovery has accelerated the identification of numerous mAbs: a discovery campaign can be deeply mined, resulting in hundreds, even thousands, of potential antibody leads for a given target of interest. High throughput mAb expression and purification methods are required for the rapid validation of those leads. In this work, we describe the implementation of a Protein-A coated membrane plate system, the Purexa™ AHT membrane plate, for robust preparative purification of hundreds of recombinant mAbs, without the need for automation. The high efficiency (>80%) recovery generated sufficient mAb for downstream screening analyses such as ELISA and surface plasmon resonance (SPR). This new system allows the functional validation of hundreds of lead antibodies from discovery campaigns in a timely manner regardless of operational size.Copyright © 2023. Published by Elsevier B.V.